Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?

被引：6
|
作者：
Munir, Kashif M. [1 ]
Davis, Stephen N. [2 ]
机构：
[1] Univ Maryland, Sch Med, Ctr Diabet & Endocrinol, Div Endocrinol Diabet & Nutr, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Med, 22 South Greene St, Baltimore, MD 21201 USA
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2018年 / 19卷 / 08期
关键词：
GLP-1 receptor agonist; SGLT2; inhibitor; type; 2; diabetes; cardiovascular outcomes; GLUCOSE-LOWERING DRUGS; CARDIOVASCULAR OUTCOMES; CVD-REAL; MORTALITY; EMPAGLIFLOZIN; LIRAGLUTIDE;
D O I：
10.1080/14656566.2018.1475559
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：773 / 777
页数：5
相关论文
共 50 条
  • [21] Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease
    Tang, Mengyao
    Morieri, Mario Luca
    Kalim, Sahir
    Doria, Alessandro
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2025,
  • [22] SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
    Brown, Emily
    Heerspink, Hiddo J. L.
    Cuthbertson, Daniel J.
    Wilding, John P. H.
    LANCET, 2021, 398 (10296): : 262 - 276
  • [23] GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy
    Scheen, Andre J.
    DRUGS, 2024, 84 (11) : 1347 - 1364
  • [24] Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
    Arnold, Suzanne V.
    Tang, Fengming
    Cooper, Andrew
    Chen, Hungta
    Gomes, Marilia B.
    Rathmann, Wolfgang
    Shimomura, Iichiro
    Vora, Jiten
    Watada, Hirotaka
    Khunti, Kamlesh
    Kosiborod, Mikhail
    BMC ENDOCRINE DISORDERS, 2022, 22 (01)
  • [25] GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection
    Bertoccini, Laura
    Baroni, Marco Giorgio
    DIABETES: FROM RESEARCH TO CLINICAL PRACTICE, VOL 4, 2021, 1307 : 193 - 212
  • [26] Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
    Suzanne V. Arnold
    Fengming Tang
    Andrew Cooper
    Hungta Chen
    Marilia B. Gomes
    Wolfgang Rathmann
    Iichiro Shimomura
    Jiten Vora
    Hirotaka Watada
    Kamlesh Khunti
    Mikhail Kosiborod
    BMC Endocrine Disorders, 22
  • [27] SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes?
    Scheen, Andre J.
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (11): : 818 - 820
  • [28] Positioning of GLP-1 receptor agonists and SGLT2 inhibitors: what do the guidelines say in diabetes?
    Darmon, P.
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2023, 27 (02): : 62 - 65
  • [29] A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment
    Consoli, Agostino
    Formoso, Gloria
    Baldassarre, Maria Pompea Antonia
    Febo, Fabrizio
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (03) : 293 - 302
  • [30] GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors
    Patel, Rushin
    Wadid, Mark
    Makwana, Bhargav
    Kumar, Ashish
    Khadke, Sumanth
    Bhatti, Ammar
    Banker, Ahan
    Husami, Zaid
    Labib, Sherif
    Venesy, David
    Fonarow, Gregg
    Kosiborod, Mikhail
    Al-Kindi, Sadeer
    Bhatt, Deepak L.
    Dani, Sourbha
    Nohria, Anju
    Butler, Javed
    Ganatra, Sarju
    JACC-HEART FAILURE, 2024, 12 (11) : 1814 - 1826
12345